Gardas A, Blottner A, Domek H
Medical Center of Postgraduate Education, Biochemistry Department, Warsaw, Poland.
Exp Clin Endocrinol. 1988 Sep;92(1):77-84. doi: 10.1055/s-0029-1210784.
Autoantibodies to different thyroid cell components in serum of patients with thyroid disease have been estimated by several methods. The TSH receptor antibodies (TRAb) have been detected in 77% of untreated Graves-Basedow, in 70% of thionamide drugs treated Graves-Basedow patients up to four months of the treatment and in 48% of patients with Hashimoto's thyroiditis. Microsomal antibodies (MAb) and thyroid plasma membrane antibodies (ATMA) have been detected in 84% and 68% respectively, in thionamide drugs treated Graves-Basedow and in 91% and 72% in Hashimoto's thyroiditis. The thyroglobulin antibodies have been detected in 42% of untreated Graves-Basedow, in 47% of thionamide drugs treated Graves-Basedow and in 77% of Hashimoto's thyroiditis. In 19% to 21% of patients with toxic nodular goiter underlying autoimmunological process have been established by the detection of high levels of serum autoantibodies (ATMA and MAb). In the non-toxic nodular goiter, non-thyroid autoimmune diseases and healthy blood donors only thyroglobulin antibodies were detected in a significant number of patients. Other types of antibodies (ATMA or MAb) were detected only in sporadic cases of non-thyroid autoimmune diseases.
已经通过多种方法对甲状腺疾病患者血清中针对不同甲状腺细胞成分的自身抗体进行了评估。在未经治疗的Graves病患者中,77%检测到促甲状腺激素受体抗体(TRAb);在接受硫酰胺类药物治疗长达四个月的Graves病患者中,70%检测到该抗体;在桥本甲状腺炎患者中,48%检测到该抗体。在接受硫酰胺类药物治疗的Graves病患者中,分别有84%和68%检测到微粒体抗体(MAb)和甲状腺质膜抗体(ATMA);在桥本甲状腺炎患者中,这一比例分别为91%和72%。在未经治疗的Graves病患者中,42%检测到甲状腺球蛋白抗体;在接受硫酰胺类药物治疗的Graves病患者中,47%检测到该抗体;在桥本甲状腺炎患者中,77%检测到该抗体。通过检测高水平的血清自身抗体(ATMA和MAb),在19%至21%的毒性结节性甲状腺肿患者中证实存在自身免疫过程。在非毒性结节性甲状腺肿、非甲状腺自身免疫性疾病患者以及健康献血者中, 仅在相当一部分患者中检测到甲状腺球蛋白抗体。其他类型的抗体(ATMA或MAb)仅在非甲状腺自身免疫性疾病的散发病例中检测到。